TO COMPARE THE EFFECT OF ABHAYADI GHANAWATI AND TABLET RANITIDINE IN MANAGEMENT OF URDHVAG AMLAPITTA

A COMPARATIVE CLINICAL STUDY OF ABHAYADI GHANAWATI AND TABLET RANITIDINE IN MANAGEMENT OF URDHVAG AMLAPITTA

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/06/019824

Enrollment

Registered

2019-06-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K00-K95- Diseases of the digestive system

Interventions

Intervention1: ABHAYADI GHANAWATI: ACCORDING TO THE REFERENCE GIVEN IN VANGASEN AND THE METHOD OF PREPARATION OF THE KWATH MENTIONED WILL BE FOLLOWED IN THE SAME MANNER.THE GHANAWATI FROM THE KWATH WE

Eligibility

Inclusion criteria

Inclusion criteria: PATIENTS HAVING SIGNS AND SYMPTOMS OF URDHVAG AMLAPITTA

Exclusion criteria

Exclusion criteria: 1.PATIENTS SUFFERING FROM GASTRIC AND DUODENAL ULCERS 2.IMMUNOCOMPRAMISED PATIENTS,BLOOD COAGULATION. 3.PREGNANT AND LACTATING WOMEN 4.CA-STOMACH, ESOPHAGUS, ESOPHAGEAL VARICES,HEMATEMESIS 5.PATIENTS HAVING HEPATIC AND RENAL DISORDERS 6.MAJOR SYSTEMIC DISEASES LIKE HTN, DM,TB

Design outcomes

Primary

Measure	Time frame
ABHAYADI GHANAWATI 500MG 1 TAB TWICE A DAY IN MANAGEMENT OF URDHVAG AMLAPITTA FOR 30 DAYSTimepoint: ABHAYADI GHANAWATI 500MG 1 TAB TWICE A DAY IN MANAGEMENT OF URDHVAG AMLAPITTA FOR 30 DAYS	—

Secondary

Measure	Time frame
TO ASSESS THE EFFICACY OF TAB.RANITIDINE IN MANAGEMENT OF URDHVAG AMLAPITTATimepoint: TO ASSESS THE EFFICACY OF ABHAYADI GHANAWATI IN THE MANAGEMENT OF URDHVAG AMLAPITTA FOR DURATION OF 30 DAYS	—

Countries

India

Contacts

Public ContactDR RUPALI KHOBRAGADE

PDEAS COLLEGE OF AYURVEDA AND RESEARCH CENTRE AKURDI PUNE

khobragaderupali19@gmail.com8378929859

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026